The decisions you may face, the aids that walk through them, the warnings on record, the first sixty days and the questions to ask.
One section per setting: the options named, what each is for, the trials behind them, the recorded trade-offs and the questions to ask.
Fainting, near-fainting, or an irregular or racing heartbeat; several kinase inhibitors prolong the QT interval and the labels require ECG and electrolyte monitoring.
Persistent headache with extreme tiredness, nausea, dizziness on standing or low blood pressure. Vomiting, severe weakness or collapse is adrenal crisis.
Fever of 38 C or higher, chills, low blood pressure, fast heartbeat or breathlessness, especially after a step-up dose. Boxed warning on teclistamab, epcoritamab, glofitamab, tarlatamab and blinatumomab.
QT: both Encorafenib and Vemurafenib prolong the QT interval (known and known risk).. Avoid other QT-prolonging drugs where possible; check ECG and correct potassium and magnesium before and during treatment.
Dabrafenib: take on an empty stomach. Trametinib: take on an empty stomach; both cause pyrexia.
No pharmacokinetic interactions expected (antibody). See the irAE guide for toxicity management.
See all on the product pages:BinimetinibBrenetafuspCobimetinibDabrafenib + trametinibEncorafenibIpilimumabNivolumabPembrolizumabRelatlimab + nivolumabTebentafuspVemurafenib·Printable cards in the navigator
What the next twelve months look like, phase by phase, with the decision points.
Newly diagnosed? Read the first 60 days with Melanoma, then print the one-page appointment sheet with room for the answers.
Print this page for your appointment (your browser's print command). These prompts are for discussion; your clinical team knows your case.